Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 7/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844861 | 0.93 | METAP2 (0.39) | SMPD3GCGRDDR1TEAD1LIPE | |
| SCHEMBL6477360 | 0.92 | GCGR (0.35) | GCGRIDH1KCNN3TEAD1LIPE | |
| SCHEMBL4845087 | 0.91 | GCGR (0.36) | GCGRIDH1PPARDPPARALIPE | |
| SCHEMBL6478251 | 0.91 | LIPE (0.37) | GCGRIDH1KCNN3TEAD1PPARD | |
| SCHEMBL4845094 | 0.90 | LIPE (0.36) | GCGRIDH1PPARDPPARALIPE | |
| SCHEMBL4848881 | 0.90 | GCGR (0.38) | GCGRIDH1LIPE | |
| SCHEMBL6478087 | 0.89 | GCGR (0.36) | GCGRIDH1KCNN3PPARDPPARA | |
| SCHEMBL4850936 | 0.88 | F2R (0.43) | GCGRIDH1KCNN3LIPE | |
| SCHEMBL6488797 | 0.88 | CCR2 (0.36) | GCGRLMNAIDH1PPARDPPARA | |
| SCHEMBL6487042 | 0.88 | FPR2 (0.33) | GCGRIDH1PPARDPPARALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | SMPD3 955/4885GCGR 3730/4885LMNA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.